Additionally, treatment with the MIF inhibitor ISO-1 reduced diabetic nephropathy in T2D and ameliorated pathological hallmarks, including hyperglycemia, increased inflammatory cytokines, and increased macrophage activation in the kidney (169). This evidence concerns the gene MIF and type 2 diabetes mellitus.